ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
US Tech 100
18,092.40
0.07%
Dow Jones
39,869.38
-0.10%
Brent Oil
83.215
0.01%
Bitcoin
66,401.24
1.78%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Sangamo Therapeutics Inc (SGMO) Quote

Sangamo Therapeutics Inc

Sangamo Therapeutics Inc (SGMO)

NASDAQ
0.6087
0.0286
(4.93%)
Closed May 16 4:00PM
Delayed by 15 minutes
0.62
0.0113
( 1.86% )
Pre Market: 6:44AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.62
Bid
0.609
Ask
0.66
Volume
5,321
0.00 Day's Range 0.00
0.2911 52 Week Range 1.67
Market Cap
109.133M
Previous Close
0.6087
Open
-
Last Trade
1
@
0.65
Last Trade Time
06:43:35
Financial Volume
-
VWAP
-
Average Volume (3m)
1,951,515
Shares Outstanding
178,906,350
Dividend Yield
-
PE Ratio
-0.42
Earnings Per Share (EPS)
-1.44
Revenue
176.23M
Net Profit
-257.83M

About Sangamo Therapeutics Inc

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.sangamo.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Sangamo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SGMO. The last closing price for Sangamo Therapeutics was $0.61. Over the last year, Sangamo Therapeutics shares have traded in a share price range of $ 0.2911 to $ 1.67.

Sangamo Therapeutics currently has 178,906,350 shares outstanding. The market capitalization of Sangamo Therapeutics is $109.13 million. Sangamo Therapeutics has a price to earnings ratio (PE ratio) of -0.42.

SGMO Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 09 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 09 2024
Edgar (US Regulatory)

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Showcased 20 presentations at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional...

May 09 2024
Business Wire

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable...

May 09 2024
Business Wire

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market...

May 02 2024
Business Wire

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for...

April 22 2024
Business Wire

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the...

March 22 2024
Business Wire

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Data from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs...

March 13 2024
Business Wire

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Novel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following...

March 13 2024
Business Wire

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before...

March 12 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0916.98113207550.530.61820.52531009640.5712926CS
40.141329.5174430750.47870.61820.4600117216360.54376513CS
12-0.53-46.08695652171.151.320.4600119515150.71210449CS
260.257370.94017094020.36271.480.346219849210.69868344CS
52-0.69-52.67175572521.311.670.291120502900.81544482CS
156-10.22-94.280442804410.8412.82970.291116530813.42319541CS
260-9.66-93.968871595310.2819.430.291117075076.3991398CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DUOFangDD Network Group Ltd
$ 2.06
(416.55%)
14.7M
AKANAkanda Corporation
$ 0.37
(179.25%)
41.91M
KXINKaixin Holdings
$ 0.4883
(121.95%)
14.13M
BRSHBruush Oral Care Inc
$ 0.2416
(72.57%)
10.89M
FFIEFaraday Future Intelligent Electric Inc
$ 2.84
(72.12%)
54.12M
AMPGAmplitech Group Inc
$ 1.45
(-32.56%)
20.32k
EJHE Home Household Service Holdings Ltd
$ 0.8112
(-21.24%)
403.2k
BSFCBlue Star Foods Corporation
$ 0.1185
(-14.32%)
2.59M
BLINBridgeline Digital Inc
$ 1.00
(-12.28%)
541
CBRLCracker Barrel Old Country Store Inc
$ 50.55
(-11.73%)
6.45k
CRKNCrown Electrokinetics Corporation
$ 0.3987
(66.13%)
74.52M
GWAVGreenwave Technology Solutions Inc
$ 0.219
(47.87%)
64.23M
FFIEFaraday Future Intelligent Electric Inc
$ 2.84
(72.12%)
54.12M
AKANAkanda Corporation
$ 0.37
(179.25%)
41.91M
DUOFangDD Network Group Ltd
$ 2.06
(416.55%)
14.7M

SGMO Discussion

View Posts
teifhals teifhals 7 days ago
Also has a lot of room to go up.
👍️0
work-n-hard work-n-hard 7 days ago
For anyone who can read ahead, yesterday's filing was not a shock. Look at the chart below and it will show the market knew it was coming.
But the news that came with it, about future developments actually sent the pps higher today than all week.
Some folks can't figure out why their trades fail. It's timing.

https://www.barchart.com/stocks/quotes/SGMO/interactive-chart
👍️0
DreamyMarauder100 DreamyMarauder100 7 days ago
Sangamo Therapeutics traded @ ( $0.2911 ) on ( November 13, 2023 ), this has a massive amount of room to go down ⏬ 🍂🍁 to that level again, especially with the earnings report that came out yesterday ( May 9, 2024 )
👍️ 1
DreamyMarauder100 DreamyMarauder100 2 weeks ago
Sangamo Therapeutics Flawless Balance ⚖️ Sheet And Extremely Undervalued... Fair Value ( $30.70 ) A Share
👍️ 1
DreamyMarauder100 DreamyMarauder100 3 weeks ago
Sangamo Therapeutics traded @ ( $0.2911 ) on ( November 13, 2023 ), this has a massive amount of room to go down ⏬ 🍂🍁 to that level again, especially with the earnings report coming out on Monday ( April 29, 2024 )
👍️ 1
seve333 seve333 4 weeks ago
It would seem so but as each do goes on the faith in sandy to get anything down keeps going down. Really hard to have any faith in that liar.
👍️ 1
seve333 seve333 4 weeks ago
They should not get a darn penny sandy drove the stock right back into the ground after the run to 1.40. He still cannot get a Farby deal done which is beyond absurd.
👍️0
jondoeuk jondoeuk 1 month ago
So they have chosen to not communicate with their customers as to the issue(s) and timing of a return? If they are closing down the website, then should have the courtesy of letting the paying customers know.
👍️0
jondoeuk jondoeuk 1 month ago
What?
👍️0
seve333 seve333 1 month ago
Whatever ryno
👍️0
Optionsrbest4u Optionsrbest4u 1 month ago
Investor Village site still down it seems. Has anyone heard anything re. a fix?
👍️0
work-n-hard work-n-hard 1 month ago
Thanks, but I don't think that far down the road with a stock who's PPS is at this level.
To me, these stocks are glorified Pinks.
JMO
👍️0
jondoeuk jondoeuk 1 month ago
They have cash until the end of Q3, but if additional funding isn't in place by then (at the latest) it's lights out. Shareholders should consider voting "against" a number of corporate incentives on the table. Officers should not be receiving bonuses this time around.
👍️0
work-n-hard work-n-hard 2 months ago
Looking like the climb back up, is still on track in the new month.
👍️0
jondoeuk jondoeuk 2 months ago
They have had countless secondaries over the years, but never an approved therapy. This company has been nothing more than a capital consuming beast created by Edward Lanphier, and he as well as others, mainly management taking shareholders to the cleaners, while they live in luxury! https://finance.yahoo.com/news/sangamo-therapeutics-announces-pricing-24-120500032.html
👍️0
work-n-hard work-n-hard 2 months ago
https://www.nasdaq.com/press-release/sangamo-therapeutics-announces-pricing-of-%2424.0-million-registered-direct-offering
👍️0
jondoeuk jondoeuk 2 months ago
From the 10-K: ''Based on our current operating plan, our cash, cash equivalents and marketable securities as of December 31, 2023 are expected to allow us to meet our liquidity requirements only into the third quarter of 2024. Although we have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs, we have been unsuccessful in securing any such additional capital to date. As a result, we have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.''
👍️0
AliasUser1 AliasUser1 2 months ago
Bought some today. Risk/Reward is definitely worth it here.
👍️0
DNORWOOD DNORWOOD 2 months ago
Happy March another day another dollar close. Cheers.
👍️0
The Canes The Canes 3 months ago
It was critical! I hate reverse splits. That's where we were headed if we didn't hold a buck today. BRAVO!
👍️0
DNORWOOD DNORWOOD 3 months ago
Hey we close above a dollar over 10 days. Yes.
👍️0
DNORWOOD DNORWOOD 3 months ago
Today is our day. I’m long SGMO and ATUS and ELTP and PLCE
👍️0
DNORWOOD DNORWOOD 3 months ago
Spreading the word. Buy SGMO. Hitting up Reddit we need them behind us. Cheers.
👍️0
The Canes The Canes 3 months ago
As I said there won't be any announcement regarding the earnings until after we close tomorrow. It's critical we stay above a dollar for 10 straight days. So tomorrow I expect the shorts to try and drive us below a dollar near the close. I have lots of ammo ready to buy the offer to fight the bastards off! You do the same amigo!
👍️0
DNORWOOD DNORWOOD 3 months ago
Big buyers. Are earning today????
👍️0
DNORWOOD DNORWOOD 3 months ago
You are correct. We are good.
👍️0
The Canes The Canes 3 months ago
We'll be good when we attain compliance after the close on Thursday. God willing the shorts don't upend that! Then and only then will the fool of a CEO announce the earnings call.
👍️0
DNORWOOD DNORWOOD 3 months ago
We are good
👍️0
DNORWOOD DNORWOOD 3 months ago
We have some good news coming. Cheers.
👍️0
DNORWOOD DNORWOOD 3 months ago
Good news coming my friends. Cheers.
👍️0
DNORWOOD DNORWOOD 3 months ago
I think early earnings next week maybe Monday. Looking good and feeling good.
👍️0
AliasUser1 AliasUser1 3 months ago
Could turn out to be good and go to 5+ somewhat quickly if things develop correctly. Cash burn will be pretty much cut in half this year too
👍️0
DNORWOOD DNORWOOD 3 months ago
I smell buyout or merger. Here we go. Volume is off the charts. All institutions and backdoor deals.
👍️0
DNORWOOD DNORWOOD 3 months ago
Here we
Go. Cheers.
👍️0
DNORWOOD DNORWOOD 3 months ago
Is Pfizer buying us out or just a friend?!?!????? Cheers.
👍️0
DNORWOOD DNORWOOD 3 months ago
We are going to the moon. Earnings coming and much much more. Cheers.
👍️0
Monksdream Monksdream 3 months ago
SGMO under $2
👍️0
Liam859 Liam859 3 months ago
$SGMO $1.45 busting ignore the noise
👍️0
trendzone trendzone 3 months ago
Earlier in the week some total creep manipulators were keeping it pinned at $0.73, if the were shorting they got their butt handed to them, if they were just some dumbass seller, they look like a total fool right now,with it at $1.35, corrupt Wall Street BS as usual, the biggest criminals walking on the earth today, steel from the public and give to their kind.
👍️0
Liam859 Liam859 3 months ago
$.82 the run begins
👍️0
Liam859 Liam859 4 months ago
$SGMO $0.55 buying it up here
👍️0
Penny Trades Penny Trades 6 months ago
Yeah maybe I should shirt the stock like you did, good idea, could have made big bucks lol
👍️0
Monksdream Monksdream 6 months ago
SGMO new 52 week low
👍️0
Monksdream Monksdream 7 months ago
I quite agree with your assessment of clinical stage bio companies as expensive experiments.
Out of curiosity I checked the reverse stock split history for Sangamo and came up with zero, which I found interesting.
Ever since Amgen went public in 1984 investors have placed high hopes on the possibility of hitting the Big One.

The biotech, biomed, medical device sector is actually the largest sector in terms of available public traded companies in which one
can invest. More go public every week.
The stock has certainly experienced some dramatic ups and downs since 2000

👍️0
Monksdream Monksdream 7 months ago
SGMO new 52 week low
👍️0
NY1972 NY1972 8 months ago
Most bios are expensive experiments done by expensive PhDs. They are Wall St. shows nobody should stick around for the endings.
👍️0
jondoeuk jondoeuk 8 months ago
Over 28 years with no success, allowing others to overtake them, while they created an unsustainable infrastructure. They couldn't even license their AAV capsids or ZFP-TFs, instead having to settle for a nominal "evaluation agreements" with Prevail and Chroma.

Worse still, have around a year of cash on hand unless they decide to address their costs. Does anyone know when the company plans on breaking even? Will it be in '26 or '27 if their haemophilia therapy is approved in '25? Also, they will need to rise, and with the current price it's going to be (extremely) dilutive. If the therapy isn't approved, I don't see how the company isn't toast.
👍️0
Monksdream Monksdream 8 months ago
SGMO new 52 week low
👍️0
Monksdream Monksdream 8 months ago
SGMO new 52 week low
👍️0
The Canes The Canes 8 months ago
It was uplifting and important to close at a dollar yesterday.
👍️0

Your Recent History

NASDAQ
SGMO
Sangamo Therapeutics
BOV
RNEW11
RENOVA
NYSE
JBP.L
NYSE
CCG-A
BOV
ANIM3
ANIMA ON
BOV
ELET3
ELETROBRAS ON
NYSE
PJJ.CL
AMEX
VRY.UN
LSE
0JBY
Elanders Ab
BOV
PDGR3
PDG REALT ON
NYSE
EBR-B
NYSE
CCT.CL
NYSE
CIM.PRB
Chimera Investment Corp.
NYSE
CYP
Lehman Abs GM
NYSE
CCH.U
Collier Creek
NASDAQ
CERS
Cerus
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved